Early Phase 1 N=20 Influence of Medication on Functional Connectivity
Prescription Drug Abuse (Not Dependent)
Primary: Change in Functional Connectivity Following Oxycodone Administration — 2.66; 4.55; .99; 1.60 z-score
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=19 Cough Desensitization Therapy for Cough Hypersensitivity Syndrome
Cough
Primary: Leicester Cough Questionnaire (LCQ) — 3.2; 2.06 score on a scale — p=.23
Early Phase 1 N=10 COVID-19 Convalescent Plasma
Coronavirus
Primary: Success of Administering Plasma — 10; 0 Participants
Early Phase 1 N=20 taVNS for Upper Limb Rehabilitation
Stroke
Primary: Change in Fugl-Meyer Assessment of the Upper Extremity — 5; 3.14 score on a scale
Early Phase 1 N=5 Procalcitonin to Reduce Antibiotic Use in Pediatric Pneumonia
Pneumonia · Pediatric Respiratory Diseases · Antibiotic Use
Primary: Total Pilot Trial Enrollment — 0; 1 Participants
Early Phase 1 N=22 Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease
Sickle Cell Disease · Sickle Cell Anemia
Primary: Mean Red Blood Cells Lifespan in Participants — 64.1; 113.4; 126.0; 123.7 day — p=<0.001
Early Phase 1 N=21 Reduced Nicotine Cigarette Purchasing Decisions
Tobacco Use Disorder
Primary: Demand Intensity — 6.48; 8.10; 7.81; 6.48 cigarettes
Early Phase 1 N=5 Examining Bioactivity of PVSRIPO in Invasive Breast Cancer
Invasive Breast Cancer
Primary: Change in Tumor Infiltrating Immune Cells — 2.6 fold-change of % CD45+ cells
Early Phase 1 N=40 Mechanism and Effects of Manipulating Chloride Homeostasis in Acute Heart Failure
Heart Failure
Primary: Change in Blood Volume — -320; -447 mL — p=0.56
Early Phase 1 N=14 Project ADHERE: Clinical Proof-of-Concept of a Tenofovir (TFV) Aptamer-Based Biosensor
HIV/AIDS · Adherence, Medication · Drug Use
Primary: Baseline TFV (Tenofovir) Levels in Plasma
Early Phase 1 N=32 Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors
Chronic Lymphocytic Leukemia (CLL) · Waldenstrom Macroglobulinemia (WM)
Primary: Number of Participants With Humoral Response to Vaccination 4 Weeks After the Second Vaccine Administration — 24 Participants
Early Phase 1 N=27 Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2
Breast Cancer · Non-Small-Cell Lung Cancer · Glioblastoma
Primary: Tracer Dosimetry by Organ — 0.3603; 0.0988; 0.8615; 0.5290 mSv/MBq
Early Phase 1 N=6 Evaluating Wearable Robotic Assistance on Gait
Cerebral Palsy
Primary: The Metabolic Energy Required to Walk — 2.42; -2.14 % change pre vs post gait training — p=0.204
Early Phase 1 N=8 Oxytocin on HR in Sleep Apnea Patient
Sleep Apnea
Primary: Frequency of Hypopnea Events — 8.5 Incidence of hypopnea events
Early Phase 1 N=24 Age-Related Effects of THC
Tolerance · Adolescent Behavior · THC
Primary: Change From Baseline in Profile of Mood States (POMS) — 5.75; 12.46; 18.55; 4.08 units on a scale